RxDoctor Payments Data

Muthiah Sabanayagam, MD

Psychiatry · Goldsboro, NCNPI 1356394050

Payments from drug & device makers

$1,878in general payments, 2019–2025

Across 22 payments — averaging $85.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$422
  • Otsuka America Pharmaceutical, Inc.$372
  • Neurocrine Biosciences, Inc.$355
  • Sunovion Pharmaceuticals Inc.$327
  • AbbVie$221
  • Alkermes, Inc.$125
  • plus $55 from 1 others

What the payments were for

  • Food & beverage$1,83198%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,878 in reported general payments places this provider in the 80th percentile of 1,108 psychiatry providers in North Carolina.

See all psychiatry providers in North Carolina

Medicare billing

Part B allowed, 2024
$84,193
Medicare patients
231
Services billed
1,410

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine86$623,030
Invega SustennaPaliperidone Palmitate43$121,571
RexultiBrexpiprazole78$118,485
VraylarCariprazine Hcl65$97,152
CaplytaLumateperone Tosylate54$92,648
Abilify MaintenaAripiprazole31$90,070
Chlorpromazine Hcl185$70,113
Haloperidol1,037$34,720
AristadaAripiprazole Lauroxil11$32,542
Lurasidone Hcl242$31,914
LybalviOlanzapine/Samidorphan Malate19$30,706
Divalproex Sodium ErDivalproex Sodium311$30,648
Paliperidone ErPaliperidone63$24,547
Clozapine111$22,931
Aripiprazole375$21,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$372$208,555109 claims
AbbVieVraylar$221$97,15265 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$422$92,64854 claims
Alkermes, Inc.Aristada, Lybalvi$125$63,24830 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,108 psychiatry providers in North Carolina.

Other psychiatry in Goldsboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →